Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Arsm Research

Neither a doctor nor a teaching hospital

Research payments

$109,141

16 payments

Through program year 2023, Arsm Research is reported as receiving $109,141 in research payments, across 16 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $67 1
2022 Research $2,215 2
2021 Research $562 2
2020 Research $19,998 4
2019 Research $86,299 7

Breakdown

Who paid Research payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $54,480 5 payments
  2. Novartis Pharmaceuticals Corporation $41,749 9 payments
  3. GlaxoSmithKline, LLC. $12,911 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $47,978 4 payments
  2. A Multi-Center, Proof-Of-Mechanism Study of Multiple, Oral Doses of Fevipiprant (Qaw039) in COPD Patients With Sputum Eosinophilia $38,478 2 payments
  3. A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $12,911 2 payments
  4. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $6,502 1 payment
  5. A 12-Week Randomized, Participant-And Investigator-Blinded, Placebo-Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled Csj117 in Adults With Chronic Obstructive Pulmonary Diseas $1,913 1 payment
  6. A Multi Center Randomized Double Blind Double Dummy 2 Period Cross Over and Active Controlled Study to Assess the Efficacy Safety and Tolerability of Indacaterol and Or Glycopyrronium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmona $729 3 payments
  7. A 12-Week Randomized, Participant-And Investigator-Blinded, Placebo-Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled Csj117 in Adults With Chronic Obstructive Pulmonary Disease (COPD) $403 2 payments
  8. A Multi Center Randomized Double Blind Double Dummy 2 Period Cross Over and Active Controlled Study to Assess the Efficacy Safety and Tolerability of Indacaterol and Or Glycopyrronium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease $226 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record